Skip to main content
Gene Therapy Net RSS feed Follow Gene Therapy Net on Twitter LinkedIn - Gene Therapy Net discussion group Facebook - Gene Therapy Net

Newsletter March 2013

Gene Therapy Net Banner
News: Lentigen wins US Orphan Drug Designation for glioblastoma
Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery products, announced today that that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to P140K methylguanine methyltransferase (MGMT) transduced human CD34 cells (product name: LG631-CD34) for bone marrow protection in the treatment of glioblastoma multiforme. Orphan drug designation qualifies Lentigen for seven years of market exclusivity following marketing approval by the FDA and provides other development-related incentives.

Conference: Australasian Gene Therapy Society
The 8th Australasian Gene Therapy Society meeting is scheduled for May 8-10, 2013 in Sydney at the Aerial Function Centre. This is a must-do event for medical researchers and clinicians fascinated by the recent progress in gene therapy and stem cell biology. We are expecting over 200+ professionals in gene therapy, cell-based therapies and related fields to attend. The agenda includes world-class speakers who will present up-to-date groundbreaking gene therapy trials on inherited and acquired genetic disorders as well as recent developments in viral and nonviral gene therapy vectors.

If you haven't become a member of AGTS, now is a good time to do so. Don't forget - members are eligible for a discounted registration for the biennial meeting. See attached registration form.

Confirmed speakers:
• Frederick Bushman “DNA integration in human gene therapy”Perelman School of Medicine, University of Pennsylvania, USA.
• Nathalie Cartier “Gene therapy strategies for genetic leukodystrophies”Director of research, INSERM, France.
• Bobby Gaspar “Gene therapy for primary immunodeficiencies" Molecular Immunology Unit, University College London Institute of Child Health, UK.
• Edward Tuddenham “Bench to bedside transition of gene therapy for Haemophilia B”University College London, UK.
• Martin Pera “Stem Cell Gene Therapy and Regenerative Medicine”Stem Cells Australia, University of Melbourne.
• Paul Reynolds “Gene and Cell Therapy for Pulmonary Hypertension”The Hanson Institute, Adelaide, South Australia.


Poll: Future Gene Therapy Approvals
The market approval of gene therapy product Glybera in Europe will accelerate regulatory approvals of other gene medicines. What do you think? Vote now!
1- Yes, it will be easier, or
2- No, regulatory process is still a big hurdle

Vote now...

- 15 - 16 March 2013, Spring Symposium of the Netherlands Society of Gene & Cell Therapy (NVGCT), Lunteren, The Netherlands
- 22 March 2013, French Society of Cell and Gene Therapy (SFTCG) Annual Congress 2013, Paris, France
- 17 - 19 April 2013, Annual conference of the British Society for Gene Therapy (BSGT), London, UK
- 22 April 2013, 8th Annual Conference of The Israeli Society of Gene Therapy (ISGCT), Jerusalem, Israel
- 22 - 25 April 2013, International Society for Cellular Therapy (ISCT) 19th Annual Meeting, Auckland, New Zealand
- 5 - 10 May 2013, Gordon Research Conference: Virusses & Cells, Lucca (Barga), Italy
- 8 – 10 May 2013, 8th Australasian Gene Therapy Society Meeting (AGTS), Sydney, Australia
- 15 – 18 May 2013, American Society of Gene and Cell Therapy (ASGCT) 16th Annual Meeting, Salt Lake City, Utah
- 4 – 6 July 2013, The 19th Annual Meeting of the Japan Society of Gene Therapy (JSGT), Okayama, Japan
- 12 – 14 August 2013, International Conference on Genetic Engineering & Genetically Modified Organisms, Raleigh, North Carolina
- 23 – 25 October 2013, 2nd International Conference and Exhibition on Cell & Gene Therapy, Orlanda, Florida
- 24 – 28 October 2013, VII Congress of the Spanish Society of Gene (SETGyC) and Cell Therapy, and XXI Congress of the European Society of Gene and Cell Therapy (ESGCT), Madrid, Spain
- 20 – 22 November 2013, 12th Annual Gene Therapy Symposium for Heart, Lung, and Blood Diseases, Sonoma, California


Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network in the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines. Other information websites created and maintained by the owner of Gene Therapy Net are Dengue Virus Net, Influenza Virus Net and Chikungunya Virus Net.
To unsubscribe from the Newsletter, please login and edit your subscription details or contact us. You are currently registered as: {subtag:name}, email address: {subtag:email}.

Advertise on this site?